한글목차

세계의 연구용 항체 및 시약 시장 규모는 2023년 126억 3,000만 달러에서 2024-2031년의 예측 기간 중 7.08%의 CAGR로 추이하며, 2031년에는 218억 2,000만 달러 규모로 성장할 것으로 예측됩니다.

세계 연구용 항체 및 시약 시장의 발전은 만성질환 및 감염성 질환 증가, 세포 및 유전자 치료 시장의 확대, 기술 발전, 정부 및 기타 관련 산업의 R&D 활동에 대한 투자 증가 등 다양한 요인에 의해 주도되고 있습니다. 또한 여러 대기업의 존재, 합작 투자, 바이오 의약품 및 생명공학 산업에 대한 관심 증가는 세계 연구용 항체 및 시약 시장의 성장을 가속화하고 있습니다.

항체 및 시약은 자가면역질환, 암, 감염성 질환 등 다양한 만성질환의 진단 및 치료에 널리 사용되고 있습니다. 따라서 항체 및 시약 시장에서 연구용 수요가 증가하고 있으며, AI 응용과 같은 기술 발전으로 연구자들은 항체 및 시약의 테스트 및 검증 품질을 향상시킬 수 있습니다. 바이오 제약 산업 및 의약품 개발 산업과 같은 생명과학 산업의 발전, 정부 및 관련 산업의 투자 및 자금 조달 증가는 시장 성장의 요인으로 작용하고 있습니다. 또한 M&A 및 파트너십 계약과 같은 빈번하고 지속적인 공동 연구 활동은 이 시장에서의 연구를 촉진하고 세계 연구용 항체 및 시약 시장을 더욱 촉진하고 있습니다.

만성질환의 유병률 증가:

연구용 항체 및 시약에 대한 수요는 만성질환의 유병률 증가로 인해 크게 증가하고 있습니다. 고령화 인구 증가는 감염성 질환, 심혈관 질환, 암, 자가면역 질환 등 여러 만성 건강 상태의 발병 원인이 되고 있습니다. WHO의 2023년 통계에 따르면 만성질환은 전 세계 인구가 앓고 있는 가장 흔한 질병으로 매년 4,100만 명이 사망하고 있으며, 전 세계에서 매년 4,100만 명이 사망하고 있습니다. 앉아서 생활하는 생활습관, 건강에 해로운 식습관, 비만, 담배와 알코올 과다 섭취는 인구의 만성질환 유병률 증가의 주요 위험요인입니다. 만성질환에 대한 효과적인 치료법이 충분히 확립되어 있지 않기 때문에 효과적이고 효율적인 의약품과 혁신적인 진단 및 치료법의 실현에 대한 중요성이 강조되고 있으며, 이에 따라 항체 및 시약 산업에서 첨단 연구 필요성이 증가하고 있습니다. 이러한 모든 요인으로 인해 세계 연구용 항체 및 시약 시장은 호황을 누리고 있습니다.

기술적 진보 :

연구용 항체 및 시약 기술은 빠르게 발전하고 있으며, CRISPR-Cas9 및 단일 세포 분석의 개발과 같은 기술 발전으로 인해 수요가 증가하고 있으며, 몇몇 주요 기업은 이 산업의 발전과 성장을 가속화하기 위해 혁신적인 제품을 출시하고 있습니다. 개발하고 있습니다. 예를 들어 생명공학 대기업 Cytek Biosciences, Inc.는 2023년 12월 시약 칵테일 제조 시스템인 Cytek Orion을 발표했습니다. 이 시스템은 시약 칵테일 제조를 완전 자동화하는 혁신적인 기술로 실험실 워크플로우를 간소화하고, 만족스러운 결과를 제공하며, 정확도를 높이고, 생산 공정을 가속화하는 데 도움을 줍니다.

세계의 연구용 항체 및 시약 시장을 조사했으며, 시장의 정의와 개요, 시장 규모의 추이·예측, 각종 구분·지역별 상세 분석, 산업 구조, 시장 성장에 대한 영향요인의 분석, 사례 연구, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 조사 방법

제2장 프로젝트의 범위와 정의

제3장 주요 요약

제4장 세계의 연구용 항체 및 시약 시장 전망

• 시장 규모·예측
• 제품별
  • 시약
  • 항체
• 기술별
  • 웨스턴 블로팅
  • 유세포분석
  • 효소면역측정법(ELISA)
  • 면역조직화학
  • 면역형광법
  • 면역침강법
  • 기타
• 용도별
  • 단백질체학
  • 의약품 개발
  • 유전체학
• 최종사용자별
  • 제약 및 바이오테크놀러지 산업
  • 학술연구기관
  • CRO
• 지역별
  • 북미
  • 유럽
  • 아시아태평양
  • 남미
  • 중동 및 아프리카
• 기업별 시장 점유율

제5장 세계의 연구용 항체 및 시약 시장 전망 : 지역별

• 북미
• 유럽
• 아시아태평양
• 남미
• 중동 및 아프리카

제6장 시장 매핑

• 제품별
• 기술별
• 용도별
• 최종사용자별
• 지역별

제7장 거시환경과 산업 구조

• 수급 분석
• 수출입 분석
• 밸류체인 분석
• PESTEL 분석
• Porter's Five Forces 분석

제8장 시장 역학

• 성장 촉진요인
• 성장 억제요인(과제와 억제)

제9장 규제 프레임워크·혁신

• 임상시험
• 특허 상황
• 규제기관 승인
• 혁신/신규 기술

제10장 주요 기업의 상황

• 시장 리더 상위 5사의 경쟁 매트릭스
• 시장 리더 상위 5사의 시장 매출 분석
• M&A·조인트 벤처(해당하는 경우)
• SWOT 분석(참여 5사)
• 특허 분석(해당하는 경우)

제11장 가격 분석

제12장 사례 연구

제13장 주요 기업의 전망

• General Electric Company
• Merck Group
• Thermo Fisher Scientific Inc.
• F. Hoffmann La-Roche AG.
• Rockland Immunochemicals Inc.
• Agilent Technologies Inc.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• PerkinElmer AES.
• Santa Cruz Biotechnology Inc.

제14장 전략적 제안

제15장 Market Xcel - Markets and Data 소개·면책사항

영문목차

Global research antibodies and reagents market is projected to witness a CAGR of 7.08% during the forecast period 2024-2031F, growing from USD 12.63 billion in 2023 to USD 21.82 billion in 2031F. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.

Growth in the global research antibodies and reagents market is driven by various factors, such as the increasing prevalence of chronic diseases and infectious diseases, the growing cell and gene therapy market, technological advancements, and increased investments by the government and other related industries to conduct research and development activities. Moreover, the presence of several leading players, collaborative ventures, and growing interest in the biopharmaceutical and biotechnological industry accelerates the global research antibodies and reagents market growth.

Antibodies and reagents are widely used to diagnose and treat various chronic diseases, such as autoimmune diseases, cancers, and infections. Due to this, there is increased demand for research in the antibodies and reagents market. Technological advancements such as the application of artificial intelligence (AI) enable researchers to improve the quality of antibodies and reagents testing and validation. Growth in the life science industry, such as the biopharmaceutical and drug development industries, along with increased investments and funding by the government and related industries, are the factors leading to market growth. Moreover, frequent and consistent collaboration activities such as mergers and acquisitions and partnership agreements to increase research in this market further propel the global research antibodies and reagents market.

Increasing Prevalence of Chronic Diseases

The demand for research in antibodies and reagents is increasing significantly due to the rising prevalence of chronic diseases. The increasing aging population is responsible for the onset of several chronic health conditions such as infections, cardiovascular diseases, cancer, and autoimmune diseases. These fatal chronic diseases need continuous research and development activities to bring diagnostics measures and innovative therapeutics. According to WHO 2023 statistics, chronic diseases are the most common diseases affecting people from all over the world and are responsible for 41 million deaths every year worldwide. A sedentary lifestyle, unhealthy diet, obesity, and excessive tobacco and alcohol consumption are the leading risk factors for the rising prevalence of chronic diseases among the population. The insufficient availability of successful therapies for chronic illnesses has increased emphasis on bringing effective and efficient pharmaceuticals and innovative diagnostics and treatments, consequently increasing the necessity for conducting advanced research in the antibodies and reagents industry. Due to all these factors, the global research antibodies and reagents market is flourishing.

Technological Advancements

Technological advancements in research antibodies and reagents are rapidly evolving, leading to tremendous growth in the research antibodies and reagents market. Technological advancements such as the development of CRISPR-Cas9 and single-cell analysis are increasing the demand, due to which several leading players are developing innovative product launches to accelerate advancements and growth in this industry. For instance, in December 2023 Cytek Biosciences, Inc., a leading biotechnology company, announced its latest launch "Cytek Orion", which is a reagent cocktail preparation system. It is an innovative fully automated reagent cocktailing technology that eases the laboratory workflow, leading to satisfactory results, enhancing accuracy, and speeding up the production process. This new system can mix and manage cocktail mixtures consisting of as many as 60 distinct reagent antibody conjugates. Due to these innovations and advancements, the global research antibodies and reagents market is expected to flourish in the forecasted period.

Immunohistochemistry Holds a Significant Market Share

Based on technology, immunohistochemistry holds a significant market share as it is the most preferred diagnostic test for diseases such as cancer and it is estimated that its use is significantly increasing with the increasing demand for personalized medicine. Frequent antibodies and reagents launched by the leading biopharmaceutical companies to accelerate application in immunohistochemistry technologies are leading to the faster growth of this technology. For instance, in March 2023, Aptamer Group plc, a leading provider of custom optimer selection and development services, announced the launch of a new reagent known as "Optimer-Fc", for application in automated immunohistochemistry (IHC) workflows. These innovative and potential product launches by key market players are accelerating the market growth.

Increased Application in Proteomics

Based on application, proteomics holds the maximum market share due to its technological advancements and potential in preparing personalized medicines. Due to its higher demand in the industry, several leading players are launching innovative products in this segment. For instance, in July 2023, Alfa Chemistry, a well-known chemical supplier, announced the launch of various proteomics products that will enhance life science research in the healthcare industry. These high-quality proteomics products, including staining reagents, western substrate, and TMB ELISA substrates are extensively used in protein analysis. These frequent product launches lead to escalating research activities in proteomics contributing to the overall market growth.

Asia-Pacific is Expected to be the Fastest-growing Region

Asia-Pacific is expected to be the fastest-growing region in the global research antibodies and reagents market. The rapidly increasing population and prevalence of chronic and infectious diseases in this region are accelerating the demand for increased research and development activities in developing efficient antibodies and reagents to improve drug discovery and enhance medical facilities. Asia-Pacific is an emerging market that has huge potential in the life science industry, due to which key market players are continuously developing partnership collaborations and establishing research institutes in this region to enhance research and development in this market. For instance, in September 2023, Agilent Technologies Inc. announced that it would partner with Advanced Cell Therapy and Research Institute in Singapore for three years. This partnership aims to bring innovation and advancement and enhance research studies in the field of cell and gene therapy. These collaborations within the Asia-Pacific are flourishing in the research antibodies and reagents market in this region.

Future Market Scenario (2024-2031F)

The global research antibodies and reagents market is expected to grow due to several factors. The increasing prevalence of chronic diseases worldwide is accelerating the demand for extensive research activities in the antibodies and reagents market to bring innovation and advancement in the healthcare sector. Technological advancements, such as the application of AI to ease the research process in this market, along with increased investments and funds by the government and life science industry are leading to escalating growth. Additionally, frequent collaboration activities such as partnerships to enhance research studies in this market are expected to flourish the global research antibodies and reagents market in the forecast period.

For instance, in February 2023, Bio-Techne Corporation and Cell Signaling Technology, both life science companies announced the partnership to add Simple Western validation to CST antibodies. This approach will enable researchers from different disciplines to study the molecular signaling pathways easily by using this simple Western validation platform.

Middle East and Africa

Key Players Landscape and Outlook

In the research antibodies and reagents market, several companies and research institutes, operating in antibodies and reagents research and development activities are continuously involved in collaboration activities such as developing strategic partnerships and establishing new research centers. These collaboration ventures play a crucial role in propelling the global research antibodies and reagents market's growth and expansion. These partnerships enable companies to gain informative insights regarding the latest and innovative research tools and methodology, access each other's knowledge, resources, markets, and technologies, and enhance research and development activities to bring advancement in antibodies and reagents developments. These collaborative ventures lead to innovation, expedite product development, and contribute to the enduring and robust growth of the global market.

For instance, in August 2023, Danaher Corporation, a global leader in science and technology, announced the acquisition of Abcam plc, which is a global supplier of protein consumables. This strategic acquisition will accelerate life science research and development activities to enhance diagnostics and treatment of complex diseases and propel the drug discovery process. These frequent collaborative ventures further assist in elevating the global research antibodies and reagents market.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Research Antibodies and Reagents Market Outlook, 2017-2031F

• 4.1.Market Size & Forecast
  • 4.1.1.By Value
  • 4.1.2.By Volume
• 4.2.By Product
  • 4.2.1.Reagents
    • 4.2.1.1.Media and Sera
    • 4.2.1.2.Stains and Dyes
    • 4.2.1.3.Buffers
    • 4.2.1.4.Others
  • 4.2.2.Antibodies
    • 4.2.2.1.Product
      • 4.2.2.1.1.Primary
      • 4.2.2.1.2.Secondary
    • 4.2.2.2.Source
      • 4.2.2.2.1.Rabbit
      • 4.2.2.2.2.Mouse
      • 4.2.2.2.3.Rat
      • 4.2.2.2.4.Others
• 4.3.By Technology
  • 4.3.1.Western Blotting
  • 4.3.2.Flow Cytometry
  • 4.3.3.Enzyme-Linked Immunosorbent Assay (ELISA)
  • 4.3.4.Immunohistochemistry
  • 4.3.5.Immunofluorescence
  • 4.3.6.Immunoprecipitation
  • 4.3.7.Others
• 4.4.By Application
  • 4.4.1.Proteomics
  • 4.4.2.Drug Development
  • 4.4.3.Genomics
• 4.5.By End-user
  • 4.5.1.Pharmaceutical and Biotechnologies Industries
  • 4.5.2.Academic and Research Institutions
  • 4.5.3.Contract Research Organizations
• 4.6.By Region
  • 4.6.1.North America
  • 4.6.2.Europe
  • 4.6.3.Asia-Pacific
  • 4.6.4.South America
  • 4.6.5.Middle East and Africa
• 4.7.By Company Market Share (%), 2023

5.Global Research Antibodies and Reagents Market Outlook, By Region, 2017-2031F

• 5.1.North America*
  • 5.1.1.Market Size & Forecast
    • 5.1.1.1.By Value
    • 5.1.1.2.By Volume
  • 5.1.2.By Product
    • 5.1.2.1.Reagents
      • 5.1.2.1.1.Media and Sera
      • 5.1.2.1.2.Stains and Dyes
      • 5.1.2.1.3.Buffers
      • 5.1.2.1.4.Others
    • 5.1.2.2.Antibodies
      • 5.1.2.2.1.Product
        • 5.1.2.2.1.1.Primary
        • 5.1.2.2.1.2.Secondary
      • 5.1.2.2.2.Source
        • 5.1.2.2.2.1.Rabbit
        • 5.1.2.2.2.2.Mouse
        • 5.1.2.2.2.3.Rat
        • 5.1.2.2.2.4.Others
  • 5.1.3.By Technology
    • 5.1.3.1.Western Blotting
    • 5.1.3.2.Flow Cytometry
    • 5.1.3.3.Enzyme-Linked Immunosorbent Assay (ELISA)
    • 5.1.3.4.Immunohistochemistry
    • 5.1.3.5.Immunofluorescence
    • 5.1.3.6.Immunoprecipitation
    • 5.1.3.7.Others
  • 5.1.4.By Application
    • 5.1.4.1.Proteomics
    • 5.1.4.2.Drug Development
    • 5.1.4.3.Genomics
  • 5.1.5.By End-user
    • 5.1.5.1.Pharmaceutical and Biotechnologies Industries
    • 5.1.5.2.Academic and Research Institutions
    • 5.1.5.3.Contract Research Organizations
  • 5.1.6.United States*
    • 5.1.6.1.Market Size & Forecast
      • 5.1.6.1.1.By Value
      • 5.1.6.1.2.By Volume
    • 5.1.6.2.By Product
      • 5.1.6.2.1.Reagents
        • 5.1.6.2.1.1.Media and Sera
        • 5.1.6.2.1.2.Stains and Dyes
        • 5.1.6.2.1.3.Buffers
        • 5.1.6.2.1.4.Others
      • 5.1.6.2.2.Antibodies
        • 5.1.6.2.2.1.Product
        • 5.1.6.2.2.1.1.Primary
        • 5.1.6.2.2.1.2.Secondary
        • 5.1.6.2.2.2.Source
        • 5.1.6.2.2.2.1.Rabbit
        • 5.1.6.2.2.2.2.Mouse
        • 5.1.6.2.2.2.3.Rat
        • 5.1.6.2.2.2.4.Others
    • 5.1.6.3.By Technology
      • 5.1.6.3.1.Western Blotting
      • 5.1.6.3.2.Flow Cytometry
      • 5.1.6.3.3.Enzyme-Linked Immunosorbent Assay (ELISA)
      • 5.1.6.3.4.Immunohistochemistry
      • 5.1.6.3.5.Immunofluorescence
      • 5.1.6.3.6.Immunoprecipitation
      • 5.1.6.3.7.Others
    • 5.1.6.4.By Application
      • 5.1.6.4.1.Proteomics
      • 5.1.6.4.2.Drug Development
      • 5.1.6.4.3.Genomics
    • 5.1.6.5.By End-user
      • 5.1.6.5.1.Pharmaceutical and Biotechnologies Industries
      • 5.1.6.5.2.Academic and Research Institutions
      • 5.1.6.5.3.Contract Research Organizations
  • 5.1.7.Canada
  • 5.1.8.Mexico

All segments will be provided for all regions and countries covered

• 5.2.Europe
  • 5.2.1.Germany
  • 5.2.2.France
  • 5.2.3.Italy
  • 5.2.4.United Kingdom
  • 5.2.5.Russia
  • 5.2.6.Netherlands
  • 5.2.7.Spain
  • 5.2.8.Turkey
  • 5.2.9.Poland
• 5.3.Asia-Pacific
  • 5.3.1.India
  • 5.3.2.China
  • 5.3.3.Japan
  • 5.3.4.Australia
  • 5.3.5.Vietnam
  • 5.3.6.South Korea
  • 5.3.7.Indonesia
  • 5.3.8.Philippines
• 5.4.South America
  • 5.4.1.Brazil
  • 5.4.2.Argentina
• 5.5.Middle East & Africa
  • 5.5.1.Saudi Arabia
  • 5.5.2.UAE
  • 5.5.3.South Africa

6.Market Mapping, 2023

• 6.1.By Product
• 6.2.By Technology
• 6.3.By Application
• 6.4.By End-user
• 6.5.By Region

7.Macro Environment and Industry Structure

• 7.1.Demand Supply Analysis
• 7.2.Import Export Analysis
• 7.3.Value Chain Analysis
• 7.4.PESTEL Analysis
  • 7.4.1.Political Factors
  • 7.4.2.Economic System
  • 7.4.3.Social Implications
  • 7.4.4.Technological Advancements
  • 7.4.5.Environmental Impacts
  • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5.Porter's Five Forces Analysis
  • 7.5.1.Supplier Power
  • 7.5.2.Buyer Power
  • 7.5.3.Substitution Threat
  • 7.5.4.Threat from New Entrant
  • 7.5.5.Competitive Rivalry

8.Market Dynamics

• 8.1.Growth Drivers
• 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

• 9.1.Clinical Trials
• 9.2.Patent Landscape
• 9.3.Regulatory Approvals
• 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

• 10.1.Competition Matrix of Top Five Market Leaders
• 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4.SWOT Analysis (For Five Market Players)
• 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

• 13.1.General Electric Company
  • 13.1.1.Company Details
  • 13.1.2.Key Management Personnel
  • 13.1.3.Products & Services
  • 13.1.4.Financials (As reported)
  • 13.1.5.Key Market Focus & Geographical Presence
  • 13.1.6.Recent Developments
• 13.2.Merck Group
• 13.3.Thermo Fisher Scientific Inc.
• 13.4.F. Hoffmann La-Roche AG.
• 13.5.Rockland Immunochemicals Inc.
• 13.6.Agilent Technologies Inc.
• 13.7.Bio-Rad Laboratories, Inc.
• 13.8.Danaher Corporation
• 13.9.PerkinElmer AES.
• 13.10.Santa Cruz Biotechnology Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer